Clinical Trials Logo

Abortion, Habitual clinical trials

View clinical trials related to Abortion, Habitual.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04621773 Active, not recruiting - Clinical trials for Recurrent Pregnancy Loss

Live Birth Rate in Patients With Unexplained Recurrent Pregnancy Loss

Start date: September 1, 2020
Phase:
Study type: Observational [Patient Registry]

STUDY AIM: to study the pregnancy outcomes and offspring development of patient with Unexplained Recurrent Pregnancy Loss Treated by PGS and spontaneous pregnancy, and to compare the health economic indicators and patient satisfaction of the two modes of pregnancy, so as to better guide the clinical treatment.

NCT ID: NCT04544462 Active, not recruiting - Infertility Clinical Trials

ANXA5 M2 Haplotyping in IVF Patients and Embryos

Start date: February 10, 2020
Phase:
Study type: Observational

This study aims to characterize the association between history of pregnancy complications and M2 carrier status in IVF patients and the utility of M2 haplotype preimplantation genetic testing (PGT) in embryos produced by carrier couples. Participants in this study will be screened for the M2 variant. History of pregnancy complications and miscarriages will be studied in order to determine potential associations with M2 carrier-ship.

NCT ID: NCT04360564 Active, not recruiting - Clinical trials for Pregnancy Complications

RPL: Interval to Live Birth and Adverse Perinatal Outcomes

Start date: May 13, 2020
Phase:
Study type: Observational

This will be a retrospective observational cohort study utilizing the data from the British Columbia Perinatal Data Registry (BCPDR). The BCPDR is a provincially inclusive database that aggregates obstetrics and neonatal variables from all attended births in British Columbia. The primary objective of this study is to evaluate and contrast the average time interval from the first to second birth for patients with recurrent pregnancy loss compared to healthy controls. Secondarily, the investigators will calculate the cumulative live birth rate in the cohort of women with recurrent pregnancy loss who were </= 35 at age of first birth and delivered between the years 2000-2010. Finally, the investigators will compare the incidence of adverse perinatal outcomes for those with recurrent pregnancy loss and those without. The results of this study will be valuable for clinicians and patients as it will provide information for prognosis counselling. This will also help those desiring more than one child with long term family planning.

NCT ID: NCT03970954 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Low-dose Interleukin-2 in Women With Unexplained Miscarriages

FaCIL-2
Start date: January 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to demonstrate the ability of low dose IL-2 to stimulate peripheral blood Tregs of women with unexplained repeated early spontaneous miscarriages for development of a therapy to prevent fetal rejection by low dose IL-2.

NCT ID: NCT03941470 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss

Start date: April 30, 2019
Phase:
Study type: Observational

To assess natural killer cells frequency and activation in cases of unexplained recurrent abortion in comparison to fertile cases - 2. . To study the expression of stimulatory receptors of natural killer cell. - 3-To study the expression of inhibitory receptors of natural killer cell.

NCT ID: NCT03165136 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

BBQ
Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation. Standard investigations fail to reveal any apparent cause in >50% of couples. No study has demonstrated any benefit of any medication in women with Unexplained RM, in the presence or absence of an inherited thrombophilia. Moreover, the benefit of aspirin and/or heparin has not been proved in women with Antiphospholipid (APL) antibody without other clinical manifestations of Antiphospholipid Syndrome. Hydroxychloroquine (HQ) is a molecule whose properties (anti-thrombotic, vascular-protective, immunomodulatory, improved glucose tolerance, lipid-lowering, anti-infectious) could be useful against mechanisms of Unexplained RM. There is no data concerning the benefit of HQ in RM in the presence or absence of antiphospholipid antibodies or any inherited thrombophilia. Administration in (Systemic Lupus erythematosus (SLE) women and for Malaria prevention provides extensive safety data during pregnancy. Oral administration makes possible treatment since the preconception period. For all of that and its low cost, hydroxychloroquine should be evaluated in RM whatever the woman thrombophilic status.

NCT ID: NCT02156063 Active, not recruiting - Clinical trials for Recurrent Pregnancy Loss

A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)

RESPONSE
Start date: June 2014
Phase: Phase 2
Study type: Interventional

This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous NT100 in pregnant women with a history of unexplained recurrent pregnancy loss. Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo.

NCT ID: NCT01644318 Active, not recruiting - Habitual Abortion Clinical Trials

CXCL9 and CXCL11 Levels in Patients With Autoimmune Thyroiditis and Habitual Abortions

Start date: n/a
Phase: N/A
Study type: Observational

The purpose of this study is to measure serum CXCL9 and CXCL11 levels in patients with autoimmune thyroiditis and habitual abortions

NCT ID: NCT01419392 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether sildenafil citrate is effective in improving uterine artery blood flow and oxidative stress in patients with unexplained recurrent miscarriages